Efficacy and Safety of Tislelizumab as an Immune Checkpoint Inhibitor for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Cureus · 2025 · PMC12335811 · PMID 40786397

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

(2023) [ 22 ] reported OS durations of 15.8 and 13.2 months, respectively, both with tight confidence intervals and highly significant p-values.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.